MedTrace Logo

Study of ORIC-101 in Combination With Anticancer Therapy

NCT03928314 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2023-12-15

No results posted yet for this study

Summary

The purpose of this study is to establish the recommended Phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with nab-paclitaxel or other anticancer therapies when administered to patients with advanced or metastatic solid tumors.

Conditions

Interventions

DRUG

ORIC-101

ORIC-101 once daily, 5 or 7 days/week, for 21 days of each 28-day cycle

DRUG

Nab-paclitaxel

75 or 100 mg/m2 Days 1, 8, and 15 of each 28-day cycle

Sponsors & Collaborators

  • ORIC Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Pratik S. Multani, MD · ORIC Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-02
Primary Completion
2022-09-22
Completion
2023-12-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03928314 on ClinicalTrials.gov